Ibrutinib combined with CAR-T cells in the treatment of del (17p) chronic lymphocytic leukemia with BCL-2 inhibitor resistance:a case report and literature review

Objective To improve the knowledge and experience of ibrutinib combined with CAR-T cells in the treatment of high-risk chronic lymphoblastic leukemia(CLL)patients or small lymphocytic lymphoma(SLL)with TP53 gene aberration.Methods One case of del(17 p)CLL patients with BCL-2 inhibitor resistance was treated with ibrutinib combined with CAR-T cells,successfully bridged to allogeneic hematopoietic stem cell transplantation(allo-HSCT),and the relative literatures were reviewed.